Skip to main content

26 October 2021

Plasmids: How to Solve a Bottleneck in Scalable Gene Therapy Manufacturing?

OXGENE

Sponsored/Labiotech/26 October 2021

Download PDF – 2.7 MB

Abstract

As gene therapies become increasingly successful, companies are in a competitive race to deliver manufacturing technologies that can streamline large-scale production at reduced costs and faster turnaround times. However, plasmids, the building blocks of viral vectors, remain a bottleneck in gene therapy manufacturing. Two companies have united to provide exciting alternatives.

Download the resource to continue reading.
×